VJHemOnc Podcast cover image

Novel developments in lower-risk MDS & important practical considerations when treating patients

VJHemOnc Podcast

CHAPTER

Innovative Treatments for Anemic Lower-Risk MDS

This chapter explores the current strategies for treating anemic lower-risk myelodysplastic syndromes (MDS) patients, particularly focusing on erythropoiesis-stimulating agents (ESAs) and the emerging use of Luspatercept. The discussion highlights the nuances of treatment decisions based on individual patient characteristics, EPO levels, and transfusion dependence, while comparing practices in Europe and the U.S. Additionally, the chapter examines ongoing trials and the potential implications of adjusting current treatment protocols.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner